Previous 10 | Next 10 |
Halozyme Therapeutics (NASDAQ:HALO) has announced a new share repurchase program to buyback up to $750M of its outstanding common stock over the next three years. The program follows the recent completion of the company's previous $550M three-year share repurchase program. The biopharmaceutic...
HALOZYME ANNOUNCES $750 MILLION THREE-YEAR SHARE REPURCHASE PROGRAM - Company Plans to Purchase up to $250 Million Worth of Shares by the End of 2022 Starting with Entering into a $150 Million Accelerated Share Repurchase Program Transaction in the Coming Week - - New Share ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips With its latest variant (Omicron) spreading, it seems Covid-19 will continue to play a major role in world events in 2022, just like it did in 2020, and in 2021. With this, pandemic-related drug stocks will likely remain ho...
The financial performance of HALO is growing at an extremely high rate, and this dynamic is expected to continue until at least 2027. The company's market prospects are undeniable, with more than 79 drugs approved by the FDA, and the company continues to negotiate agreements and penet...
Halozyme Announces Janssen Receives U.S. FDA Approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in Combination with Carfilzomib and Dexamethasone for Patients with Multiple Myeloma After First or Subsequent Relapse - Approval marks the ninth indication for DA...
The following slide deck was published by Halozyme Therapeutics, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Halozyme Therapeutics, Inc. 2021 Q3 - Results - Earnings Call Presentation
Image source: The Motley Fool. Halozyme Therapeutics, inc (NASDAQ: HALO) Q3 2021 Earnings Call Nov 2, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Halozyme Therapeutics, inc (HALO) Q3 2021 Earnings Call Transcrip...
Halozyme Therapeutics, Inc. (HALO) Q3 2021 Earnings Conference Call November 03, 2021, 04:30 PM ET Company Participants Al Kildani - Vice President of Investor Relations and Corporate Communications Helen Torley - President and CEO Elaine Sun - CFO Conference Call Participants Charles Duncan ...
A 145% increase in royalties in Q3 2021, primarily from sales of Darzalex (daratumumab), helped lead Halozyme Therapeutics (NASDAQ:HALO) to an earnings beat. Royalty revenue in the quarter was $58.6M, up from $23.9M in the prior-year period. Net product sales surged ~177% to ~25M. Operating e...
Halozyme Therapeutics (NASDAQ:HALO): Non-GAAP EPS of $0.55 beats by $0.07; GAAP EPS of $1.48 beats by $1.06. Revenue of $115.83M beats by $9.99M. Press Release Guidance Revenues of $430 million to $445 million, increased from prior guidance of $425 million to $445 million, representing year-o...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...